<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87166">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672151</url>
  </required_header>
  <id_info>
    <org_study_id>jsxys456</org_study_id>
    <nct_id>NCT01672151</nct_id>
  </id_info>
  <brief_title>Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia</brief_title>
  <acronym>ITP</acronym>
  <official_title>Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Suzhou Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Suzhou Medical College</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune
      Thrombocytopenic Purpura (RITP) and explore the further mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and
      autoimmune diseases. Many studies have shown that the drug contributes to the expansion of
      regulatory T cells and preserves the highly suppressive function of autoreactive T cells.
      Patients with RITP often display a decreased  proportion of regulatory T cells by flow
      cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapamycin</intervention_name>
    <description>4mg oral administration on the first day, 2 mg/d oral administration for 3 months</description>
    <other_name>sirolimus</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        35 patients using rapamycin therapy were observed before and after treatment,who did not
        response to any other administrations including prednisone and immunosuppressive drugs,
        even splenectomy .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnoses of idiopathic thrombocytopenic purpura

          -  Hormone and immune suppression, splenectomy is invalid

        Exclusion Criteria:

          -  patients had a bad tolerance to rapamycin

          -  platelet counts &lt; 10*10E9/L during the treatment of rapamycin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhaoyue wang, doctor</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Institute of Hematology</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 23, 2012</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Suzhou Medical College</investigator_affiliation>
    <investigator_full_name>Zhaoyue Wang</investigator_full_name>
    <investigator_title>Jiangsu Institute of hematology</investigator_title>
  </responsible_party>
  <keyword>Refractory Immune Thrombocytopenic Purpura</keyword>
  <keyword>rapamycin</keyword>
  <keyword>regulatory T cells</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
